|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
|
31115870 |
2019 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The CD133 expression signatures in GC expression profiles were positively correlated with those of brain tumors expressing CD133 and human embryonic stem cells, emphasizing the transcriptional similarities across stem cell-related expression signatures.
|
30717708 |
2019 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD133 in brain tumor: the prognostic factor.
|
28055976 |
2017 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD133, a putative stem cell marker in normal tissue and malignant brain tumors, enhances multidrug resistant gene 1 (MDR1) expression following chemotherapy in adult malignant glioblastomas.
|
28137267 |
2017 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD133 has played a pivotal role in the identification and isolation of brain tumor stem cells.
|
26757925 |
2016 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A transmembrane protein CD133 has been implicated as a marker of stem-like glioma cells and predictor for therapeutic response in malignant brain tumours.
|
26086074 |
2015 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
|
26152745 |
2015 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous reports have implicated CD133-expressing cells as CSCs in brain tumors, while those expressing CD15 have been shown to propagate medulloblastoma.
|
25921740 |
2015 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Brain tumor xenografts initiated from glioblastoma (GBM) CD133(+) tumor stem-like cells (TSCs) are composed of TSC and non-TSC subpopulations, simulating the phenotypic heterogeneity of GBMs in situ.
|
22431923 |
2012 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of the stem cell marker CD133 in the initiation and progression of brain tumors is still uncertain.
|
21274750 |
2011 |
|
Brain Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
TSCs were confirmed to express the brain tumor stem cell marker CD133, and on in vitro differentiation gave rise to cells expressing neuronal or glial markers.
|
21088899 |
2011 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD133 is extensively used as a surface marker to identify and isolate glioma-initiating cells (GICs) from malignant brain tumors; however, instances of CD133(-) cells exhibiting similar properties have also been reported.
|
21110069 |
2011 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD133 has recently been proposed as a marker for cancer stem-like cells (CSC) in brain tumors.
|
19362240 |
2009 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that the CD133(+) cell subpopulation evokes most of the lysophospholipid response within brain tumors through a combined regulation of S1P/LPA cell surface receptors signaling and by MT1-MMP.
|
19326372 |
2009 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Here, we show that human CSF contains specific membrane particles that carry prominin-1/CD133, a neural stem cell marker implicated in brain tumors, notably glioblastoma.
|
18096722 |
2008 |
|
Brain Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, our findings do not suggest that CD133 expression is required for brain tumor initiation, but that it may be involved during brain tumor progression.
|
17955491 |
2008 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
LHGDN |
Recently, many studies have focused on isolation of brain cancer stem cells using CD133 expression.
|
18985161 |
2008 |
|
Brain Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recently, many studies have focused on isolation of brain cancer stem cells using CD133 expression.
|
18985161 |
2008 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, these data show that L1CAM is required for maintaining the growth and survival of CD133(+) glioma cells both in vitro and in vivo, and L1CAM may represent a cancer stem cell-specific therapeutic target for improving the treatment of malignant gliomas and other brain tumors.
|
18676824 |
2008 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ad16p and CV23 infected the low-passage brain tumor cell lines and also the CD133(+) and CD133(-) primary tumor cells most efficiently.
|
17878898 |
2007 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The fraction of tumour cells expressing CD133 (Prominin-1), a marker for both neural stem cells and brain cancer stem cells, is enriched after radiation in gliomas.
|
17051156 |
2006 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Future treatment should target this small population of CD133 positive cancer stem cells in tumors to improve the survival of brain tumor patients.
|
17140455 |
2006 |
|
Brain Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Only the CD133+ brain tumour fraction contains cells that are capable of tumour initiation in NOD-SCID (non-obese diabetic, severe combined immunodeficient) mouse brains.
|
15549107 |
2004 |